Positive results announced in first part of phase 2 trial for TRD treatment
Click Here to Manage Email Alerts
Biomind Labs Inc. has announced positive initial results from the first part of its phase 2 trial of a novel liquid inhaled formulation of N,N-Dimethyltryptamine, or DMT, for treatment-resistant depression.
According to a release from the company, the trial, led by Dráulio Araújo, PhD, has involved a dose exploration schedule of its formulation, BMND01, ranging from 5 mg to 100 mg. Thus far, no participant has presented serious adverse events or clinical risk to the 11 different doses tested.
“This trial aims to go through the full psychedelic experience in just 10 minutes,” Biomind CEO Alejandro Antalich, said in the release. “These successful first results bring strong potential for the next phase of the trial, which will address patients suffering from TRD.”
The company stated in the release that the experimental design of the open-label ascending dose trial involved developing and implementing a proprietary clinical-experimental protocol based on the fundamentals of interventional psychiatry. This multidisciplinary approach combines a psychiatric procedure for dosing DMT associated with psychological support under strict clinical standards.
“By allowing the creation of specialized centers for the administration of DMT, it is possible to scale-up treatments without the need to train a whole new generation of mental health professionals,” Antalich said in the release.